Cargando…
Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis
BACKGROUND: Use of rituximab (RTX) for focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) is widely described in children. Clinical evidence in adults is limited. The objective of this study was to determine the treatment outcomes of RTX in adults with FSGS and MCD. METHODS:...
Autores principales: | Hansrivijit, Panupong, Cheungpasitporn, Wisit, Thongprayoon, Charat, Ghahramani, Nasrollah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7160971/ https://www.ncbi.nlm.nih.gov/pubmed/32293308 http://dx.doi.org/10.1186/s12882-020-01797-7 |
Ejemplares similares
-
Rituximab or plasmapheresis for prevention of recurrent focal segmental glomerulosclerosis after kidney transplantation: A systematic review and meta-analysis
por: Boonpheng, Boonphiphop, et al.
Publicado: (2021) -
Rituximab treatment in adults with refractory minimal change disease or focal segmental glomerulosclerosis
por: Ren, Hong, et al.
Publicado: (2017) -
Is It Time for Machine Learning Algorithms to Predict the Risk of Kidney Failure in Patients with Chronic Kidney Disease?
por: Thongprayoon, Charat, et al.
Publicado: (2021) -
Predicting Acute Kidney Injury after Cardiac Surgery by Machine Learning Approaches
por: Thongprayoon, Charat, et al.
Publicado: (2020) -
Impact of serum phosphate changes on in-hospital mortality
por: Thongprayoon, Charat, et al.
Publicado: (2020)